elbion AG
🇩🇪Germany
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2007-08-08
- Lead Sponsor
- elbion AG
- Target Recruit Count
- 275
- Registration Number
- NCT00439192
- Locations
- 🇸🇪
Danderyds Hospital, Stockholm, Sweden
🇸🇪University Hospital Uppsala, Uppsala, Sweden
🇸🇪Karolinska University Hospital Huddinge, Stockholm, Sweden
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2006-09-29
- Lead Sponsor
- elbion AG
- Target Recruit Count
- 24
- Registration Number
- NCT00322803
- Locations
- 🇩🇪
Charité - University Clinics Berlin, Berlin, Germany
🇩🇪Emovis, The institute of emotional health, Berlin, Germany
🇳🇱Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University, Maastricht, Netherlands
© Copyright 2024. All Rights Reserved by MedPath